• Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

  • Patients achieving MRD negativity in blood after second induction show no survival benefit from CR1 transplant, even if FLT3-ITD comutated.

Abstract

Selection of patients with NPM1-mutated acute myeloid leukemia (AML) for allogeneic transplant in first complete remission (CR1-allo) remains controversial because of a lack of robust data. Consequently, some centers consider baseline FLT3–internal tandem duplication (ITD) an indication for transplant, and others rely on measurable residual disease (MRD) status. Using prospective data from the United Kingdom National Cancer Research Institute AML17 and AML19 studies, we examined the impact of CR1-allo according to peripheral blood NPM1 MRD status measured by quantitative reverse transcription polymerase chain reaction after 2 courses of induction chemotherapy. Of 737 patients achieving remission, MRD was positive in 19%. CR1-allo was performed in 46% of MRD+ and 17% of MRD patients. We observed significant heterogeneity of overall survival (OS) benefit from CR1-allo according to MRD status, with substantial OS advantage for MRD+ patients (3-year OS with CR1-allo vs without: 61% vs 24%; hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.24-0.64; P < .001) but no benefit for MRD patients (3-year OS with CR1-allo vs without: 79% vs 82%; HR, 0.82; 95% CI, 0.50-1.33; P = .4). Restricting analysis to patients with coexisting FLT3-ITD, again CR1-allo only improved OS for MRD+ patients (3-year OS, 45% vs 18%; compared with 83% vs 76% if MRD-); no interaction with FLT3 allelic ratio was observed. Postinduction molecular MRD reliably identifies those patients who benefit from allogeneic transplant in first remission. The AML17 and AML19 trials were registered at www.isrctn.com as #ISRCTN55675535 and #ISRCTN78449203, respectively.

1.
Schlenk
RF
,
Döhner
K
,
Krauter
J
, et al
.
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
.
N Engl J Med
.
2008
;
358
(
18
):
1909
-
1918
.
2.
Schlenk
RF
,
Kayser
S
,
Bullinger
L
, et al
.
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
.
Blood
.
2014
;
124
(
23
):
3441
-
3449
.
3.
Pratcorona
M
,
Brunet
S
,
Nomdedéu
J
, et al
.
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
.
Blood
.
2013
;
121
(
14
):
2734
-
2738
.
4.
Stelljes
M
,
Krug
U
,
Beelen
DW
, et al
.
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis
.
J Clin Oncol
.
2014
;
32
(
4
):
288
-
296
.
5.
Röllig
C
,
Bornhäuser
M
,
Kramer
M
, et al
.
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial
.
J Clin Oncol
.
2015
;
33
(
5
):
403
-
410
.
6.
Ivey
A
,
Hills
RK
,
Simpson
MA
, et al
.
Assessment of minimal residual disease in standard-risk AML
.
N Engl J Med
.
2016
;
374
(
5
):
422
-
433
.
7.
Balsat
M
,
Renneville
A
,
Thomas
X
, et al
.
Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group
.
J Clin Oncol
.
2017
;
35
(
2
):
185
-
193
.
8.
Schnittger
S
,
Kern
W
,
Tschulik
C
, et al
.
Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML
.
Blood
.
2009
;
114
(
11
):
2220
-
2231
.
9.
Krönke
J
,
Schlenk
RF
,
Jensen
K-O
, et al
.
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group
.
J Clin Oncol
.
2011
;
29
(
19
):
2709
-
2716
.
10.
Tettero
JM
,
Ngai
LL
,
Bachas
C
, et al
.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
.
Haematologica
.
2023
;
108
:
2794
-
2798
.
11.
Löwenberg
B
,
Pabst
T
,
Maertens
J
, et al
.
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
.
Blood Adv
.
2021
;
5
(
4
):
1110
-
1121
.
12.
Daver
N
,
Venugopal
S
,
Ravandi
F
.
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
.
Blood Cancer J
.
2021
;
11
(
5
):
104
-
109
.
13.
National Comprehensive Cancer Network (NCCN)
. NCCN Clinical Practice Guidelines in Oncology, Acute Myeloid Leukemia.
National Comprehensive Cancer Network, Inc
;
2023
.
14.
Döhner
H
,
Wei
AH
,
Appelbaum
FR
, et al
.
Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel
.
Blood
.
2022
;
140
(
12
):
1345
-
1377
.
15.
Grimwade
D
,
Hills
RK
,
Moorman
AV
, et al
.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
.
Blood
.
2010
;
116
(
3
):
354
-
365
.
16.
Knapper
S
,
Russell
N
,
Gilkes
A
, et al
.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
.
Blood
.
2017
;
129
(
9
):
1143
-
1154
.
17.
Potter
N
,
Jovanovic
J
,
Ivey
A
, et al
.
P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies
.
HemaSphere
.
2023
;
7
(
S3
):
e345570d
.
18.
Burnett
AK
,
Hills
RK
,
Wheatley
K
,
Goldstone
AH
,
Prentice
AG
,
Milligan
D
.
A sensitive risk score for directing treatment in younger patients with AML [abstract]
.
Blood
.
2006
;
108
(
11
):
18
.
19.
Dillon
R
,
Hills
R
,
Freeman
S
, et al
.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
.
Blood
.
2020
;
135
(
9
):
680
-
688
.
20.
Bornhäuser
M
,
Schliemann
C
,
Schetelig
J
, et al
.
Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial
.
JAMA Oncol
.
2023
;
9
(
4
):
519
-
526
.
21.
Levis
M
,
Shi
W
,
Chang
K
, et al
.
FLT3 inhibitors added to induction therapy induce deeper remissions
.
Blood
.
2020
;
135
(
1
):
75
-
78
.
22.
Russell
N
,
Wilhelm-Benartzi
C
,
Othman
J
, et al
.
S126: gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML: results from the NCRI AML19 “midotarg” pilot trial
.
HemaSphere
.
2022
;
6
(
S3
):
27
-
28
.
23.
Döhner
K
,
Thiede
C
,
Jahn
N
, et al
.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
.
Blood
.
2020
;
135
(
5
):
371
-
380
.
You do not currently have access to this content.
Sign in via your Institution